Yanting Huang

Yanting Huang

Auto-generated profile, based on publicly available information

Yanting Huang

State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in European Journal of Pharmacology
Verified
Journal Article
Closed access
DSDoree F. Sitkoff
Doree F. Sitkoff
NLNing Lee
Ning Lee
BEBruce A. Ellsworth
Bruce A. Ellsworth
QHQi Huang
Qi Huang
LKLiya Kang
Liya Kang
KCKenneth E. Carlson
Kenneth E. Carlson

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
XLXue-mei Lu
Xue-mei Lu
JWJie Wang
Jie Wang
XJXiao-Bao Jin
Xiao-Bao Jin
YHYanting Huang
Yanting Huang
WZWenting Zeng
Wenting Zeng
JZJiayong Zhu
Jiayong Zhu
Frequent and high-dose administration of interferon to patients with viral hepatitis results in various side effects. In our previous study, a novel liver-targeting interferon (IFN-CSP) combiningPlasmodiumregion I peptide with IFNα2b was successfully designed and expressed in theEscherichia coliexpression systems. This targeting would target the IFNα2b specifically to the liver, thus reducing the adverse events. In the present study, we further investigated the anti-HBV effects and molecular mechanisms of recombinant IFN-CSP in HepG2.2.15 cell line. Hepatitis B surface antigen (HBsAg) and HBe antigen (HBeAg) in the culture supernatants were analyzed by enzyme-linked immunosorbent assay (ELISA). HBV-DNA was measured by real-time quantitative PCR. HBV core protein was assayed by immunofluorescent and western blot analysis. The expressions of signal transducers and transactivator 1 (STAT1), STAT2, IFN regulatory factor 9 (IRF-9), and 2′-5′-oligoadenylate synthetase 1 (OAS1) were investigated by the reverse transcription PCR and western blot analysis. Results indicate IFN-CSP efficiently inhibited HBsAg and HBeAg secretion, HBV-DNA replication, and HBV core protein expression in HepG2.2.15 cells. The anti-HBV mechanisms involve activation of JAK-STAT signaling and increase of the anti-HBV protein OAS expression. IFN-CSP could be a good substitute for IFNα2b for anti-HBV treatment.

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
XLXue-mei Lu
Xue-mei Lu
XJXiao-Bao Jin
Xiao-Bao Jin
YHYanting Huang
Yanting Huang
JWJie Wang
Jie Wang
JSJuan Shen
Juan Shen
JZJiayong Zhu
Jiayong Zhu
Interferon alpha (IFNα) exerts a multiplicity of biological actions including antiviral, immunomodulatory, and antiproliferative effects. Administration of IFNαis the current treatment for chronic hepatitis B; however, therapy outcome has not been completely satisfactory. The systemic effects of IFNαmay account for its lowin vivobiological activity and multiple adverse events. The purpose of this study was to design a novel liver-targeting fusion interferon (IFN-CSP) by fusing IFNα2b with aPlasmodiumregion I-plus peptide, thus targeting the drug specifically to the liver. The DNA sequence encoding IFN-CSP was constructed using improved splicing by overlapping extension-PCR method, and then cloned into the pET-21b vector for protein expression inE. coliBL21 (DE3). The recombinant protein was expressed as a His-tagged protein and purified using a combination of Ni affinity and HiTrap affinity chromatography at a purity of over 95%. The final yield of biologically active IFN-CSP was up to 270 mg/L culture. The purified recombinant protein showed anti-HBV activity and liver-targeting potentialityin vitro. These data suggests that the novel fusion interferon IFN-CSP may be an excellent candidate as a liver-targeting anti-HBV agent.

1 January 2021 in Chinese Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
XXXin Xi
Xin Xi
GZGongping Zhang
Gongping Zhang
JLJiancheng Li
Jiancheng Li
YHYanting Huang
Yanting Huang
WJWenjun Jiang
Wenjun Jiang
HZHongping Zhu
Hongping Zhu